Dr. Ignacio is an early-mid career researcher (PhD 2015) with an outstanding track record and upward career trajectory. She has co-authored 25 publications (17 as first author, 508 citations). Her PhD produced 9 publications, received scholarship awards, won multiple best poster presentations and 3 invited speaker at international meetings, all exceptional achievements for a PhD student. In 2015, she was recruited to the Meharry Medical College, Nashville, USA to identify novel drug targets in triple-negative breast cancer and ovarian cancer, and this produced 10 publications (9 as first author). In 2018, she was appointed as a Research Officer at UNSW Sydney. Rosa developed highly advanced skills in the use of nano-based gene silencing drugs to inhibit genes which promote pancreatic tumour growth. She also gained skills in the use of clinically relevant cancer models. Rosa co-authored 2 research articles (Cancer Research, 2021, Scientific Reports, 2021) which attracted widespread media attention. Her high-quality writing skills is highlighted in a recent review published in Biomaterials (ranked 4/87 in engineering and biomedicine), 2020 (2nd author) which provided guidelines for nanoparticle design for the delivery of drugs to pancreatic tumours. In 2020 (February), Rosa joined the Children’s Cancer Institute (CCI) to apply her skills in nanoparticle drug delivery and cancer mouse models to lead a new project using nanoparticles to deliver drugs to childhood brain tumours. Unfortunately, due to the COVID-19 pandemic, Rosa was not able to start until October. However, since this time she has made significant contributions to research by demonstrating the ability of novel nanomedicines to cross the blood-brain barrier (1 manuscript accepted to Nanoscale; 2 manuscripts in preparation). Since 2018, Rosa has been invited to review manuscripts for journals and was recently appointed as the coordinator for journal club meetings for the Translational Cancer Nanomedicine Theme at CCI.